Free Trial
OTCMKTS:BAYRY

Bayer Aktiengesellschaft 8/6/2024 Earnings Report

Bayer Aktiengesellschaft logo
$8.09 +0.35 (+4.52%)
As of 08/1/2025 03:59 PM Eastern

Bayer Aktiengesellschaft EPS Results

Actual EPS
$0.25
Consensus EPS
$0.25
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Bayer Aktiengesellschaft Revenue Results

Actual Revenue
$12.00 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bayer Aktiengesellschaft Announcement Details

Quarter
Time
TAS
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, August 5, 2025, based on past reporting schedules.

Conference Call Resources

Bayer Aktiengesellschaft Earnings Headlines

Kepler Capital Remains a Buy on Bayer (0P6S)
Trump Did What!?
Last May, President Trump signed four executive orders that could spark the biggest energy disruption in decades. This move opens the door for a next-gen power source with the potential to upend oil and gas, slash emissions, and accelerate artificial intelligence breakthroughs. While stocks tied to this trend have already soared, one overlooked corner of the industry could deliver even bigger gains—and it’s still flying under the radar.
Bernstein Keeps Their Hold Rating on Bayer (0P6S)
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY), together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

View Bayer Aktiengesellschaft Profile

More Earnings Resources from MarketBeat